BR9811755A - Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica - Google Patents

Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica

Info

Publication number
BR9811755A
BR9811755A BR9811755-6A BR9811755A BR9811755A BR 9811755 A BR9811755 A BR 9811755A BR 9811755 A BR9811755 A BR 9811755A BR 9811755 A BR9811755 A BR 9811755A
Authority
BR
Brazil
Prior art keywords
peptide
animal
pharmaceutical composition
obesity
treatment
Prior art date
Application number
BR9811755-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Frank Man-Woon Ng
Woei-Jia Jiang
Original Assignee
Metabolic Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO9001A external-priority patent/AUPO900197A0/en
Priority claimed from AUPP0398A external-priority patent/AUPP039897A0/en
Application filed by Metabolic Pharmaceutical Ltd filed Critical Metabolic Pharmaceutical Ltd
Publication of BR9811755A publication Critical patent/BR9811755A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Photolithography (AREA)
BR9811755-6A 1997-09-08 1998-09-04 Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica BR9811755A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO9001A AUPO900197A0 (en) 1997-09-08 1997-09-08 Treatment of obesity
AUPP0398A AUPP039897A0 (en) 1997-11-13 1997-11-13 Treatment of obesity
PCT/AU1998/000724 WO1999012969A1 (en) 1997-09-08 1998-09-04 Treatment of obesity

Publications (1)

Publication Number Publication Date
BR9811755A true BR9811755A (pt) 2000-08-29

Family

ID=25645599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811755-6A BR9811755A (pt) 1997-09-08 1998-09-04 Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica

Country Status (12)

Country Link
US (2) US6737407B1 (enExample)
EP (1) EP1012189B1 (enExample)
JP (1) JP4334761B2 (enExample)
CN (1) CN1195776C (enExample)
AT (1) ATE377026T1 (enExample)
BR (1) BR9811755A (enExample)
CA (1) CA2303395C (enExample)
DE (1) DE69838647T2 (enExample)
ES (1) ES2296342T3 (enExample)
NZ (1) NZ502993A (enExample)
RU (1) RU2223970C2 (enExample)
WO (1) WO1999012969A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ387599A0 (en) 1999-11-05 1999-12-02 Metabolic Pharmaceuticals Limited Product and method for control of obesity
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
GB0315182D0 (en) * 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
WO2005007859A2 (en) * 2003-07-11 2005-01-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
ES2391853T3 (es) * 2004-05-04 2012-11-30 Metabolic Pharmaceuticals Ltd. Métodos para prevenir o tratar trastornos óseos
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
ES2258923B1 (es) * 2005-02-23 2007-11-01 Universitat De Les Illes Balears Uso de la leptina para la prevencion del exceso de peso corporal y composicion que contiene leptina.
US20110092448A1 (en) * 2005-08-02 2011-04-21 Metabolic Pharmaceuticals Limited Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics
WO2007068039A1 (en) * 2005-12-12 2007-06-21 Metabolic Pharmaceuticals Limited Treatment of weight gain in estrogen deficient mammals
US9371297B2 (en) 2007-02-09 2016-06-21 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
WO2008098280A1 (en) * 2007-02-16 2008-08-21 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of dicarba bridges in growth hormone peptides
US20110237524A1 (en) * 2008-09-19 2011-09-29 Nektar Therapeutics Polymer conjugates of aod-like peptides
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
ES2764106T3 (es) * 2011-12-09 2020-06-02 Metabolic Pharmaceuticals Pty Ltd Uso de fragmentos de la hormona del crecimiento
CN102827290A (zh) * 2012-09-07 2012-12-19 浙江大学 人血清白蛋白与人生长激素脂肪分解结构域的融合蛋白
GB2507341A (en) * 2012-10-29 2014-04-30 Peter Kenny Fat loss composition comprising a prostaglandin F2 alpha analogue and a fragment of amino acids 176-191 of human growth hormone
RU2020123165A (ru) * 2018-01-15 2022-02-17 Лэйтерал Ип Пти Лтд Пептиды и их применение

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG49718A3 (bg) 1983-07-15 1992-01-15 Bio- Technology General Corp Метод за получаване на полипептид със супероксиддисмутазна активност
US4863901A (en) 1986-01-09 1989-09-05 Brigham & Women's Hospital Use of growth hormone for nitrogen retention under hypocaloric conditions
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU693478B2 (en) 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity

Also Published As

Publication number Publication date
US6737407B1 (en) 2004-05-18
JP4334761B2 (ja) 2009-09-30
CA2303395A1 (en) 1999-03-18
NZ502993A (en) 2002-12-20
US20040192608A1 (en) 2004-09-30
EP1012189A1 (en) 2000-06-28
RU2223970C2 (ru) 2004-02-20
DE69838647T2 (de) 2008-08-28
CN1275132A (zh) 2000-11-29
ES2296342T3 (es) 2008-04-16
EP1012189A4 (en) 2004-10-20
ATE377026T1 (de) 2007-11-15
CA2303395C (en) 2008-12-02
JP2002501004A (ja) 2002-01-15
WO1999012969A1 (en) 1999-03-18
EP1012189B1 (en) 2007-10-31
DE69838647D1 (de) 2007-12-13
CN1195776C (zh) 2005-04-06

Similar Documents

Publication Publication Date Title
BR9811755A (pt) Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica
RU2224539C2 (ru) Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр)
BRPI9708566A (pt) Análogo de glp-2, análogo de peptìdeo glp-humano, peptìdeo, composição farmacêutica, uso de um análogo de glp-2, e, processo para identificar análogos intestinotróficos de glp-2.
BR9607647A (pt) Derivado de insulina e composição farmacêutica e processo para o tratamento de diabetes em um paciente em necessidade deste tratamento
BR9610331A (pt) Composições farmacêuticas para distribuição nasal de compostos úteis para o tratamento de osteoporose
IL109403A0 (en) Oral drug delivery compositions and methods
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE69907577D1 (de) Entzündungshemmende Zusammensetzung
ATE220917T1 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
ATE100714T1 (de) Arzneimittel (calcitoningen verwandte peptide) zur behandlung erektiler dysfunktionen.
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
PT1001802E (pt) Preparacao farmaceutica combinada compreendendo a hormona da paratiroide e um inibidor de reabsorcao ossea
KR880013974A (ko) 합성펩티드와 이를 포함하는 제약학적 조성물
KR960000921A (ko) 칼시토닌 유도체 및 그 용도
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
AU2003292326A1 (en) Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
PT980253E (pt) Somatostatina e agonistas de somatostatina para tratar a insensibilidade a insulina e a sindrome x
PT804182E (pt) Utilizacao de gabapentina para o tratamento da ansiedade e do panico
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
BR0014803A (pt) Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico
RU95120588A (ru) Циклогексапептиды, их смеси, способ их получения и применения
KR920700224A (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.